Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Liabilities and Shareholders Equity (2019 - 2026)

BioScience Health Innovations has reported Liabilities and Shareholders Equity over the past 8 years, most recently at $2.3 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 67.05% to $2.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Mar 2026, up 181.62% year-over-year, with the annual reading at $1.7 million for FY2025, 95.38% up from the prior year.
  • Liabilities and Shareholders Equity was $2.3 million for Q1 2026 at BioScience Health Innovations, up from $1.7 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $2.3 million in Q1 2026 and troughed at $16253.0 in Q3 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $154798.0 (2024), against an average of $684338.2.
  • The largest YoY upside for Liabilities and Shareholders Equity was 6439.04% in 2022 against a maximum downside of 70.52% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $28343.0 in 2022, then surged by 229.49% to $93388.0 in 2023, then surged by 835.65% to $873788.0 in 2024, then soared by 95.38% to $1.7 million in 2025, then skyrocketed by 36.5% to $2.3 million in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Liabilities and Shareholders Equity are $2.3 million (Q1 2026), $1.7 million (Q4 2025), and $2.1 million (Q3 2025).